Sato M, Oe H, Nakano M, Kawasaki H, Hirayama C
Hepatogastroenterology. 1981 Jun;28(3):135-8.
In a study designed to determine the preventive effect of lysozyme on post-transfusion hepatitis, 260 patients with orthopedic diseases, who received blood by transfusion during a period of 5 years from June 1970 to May 1975, were divided at random into a group of 123 patients treated with lysozyme is doses of 60 to 170 mg/day for 4 to 24 weeks, and a control group of 137 patients. The incidence of post-transfusion hepatitis was 10 (8.1%) out of 123 patients for the treated group, and 28 (20.4%) out of 137 patients for the control group. Icteric hepatitis occurred in 1 (0.8%) patient in the treated group, while its incidence in the control group was 8 (5.8%) out of 137 patients.
在一项旨在确定溶菌酶对输血后肝炎预防作用的研究中，选取了260例骨科疾病患者，这些患者在1970年6月至1975年5月期间接受了输血治疗。他们被随机分为两组，一组为123例接受溶菌酶治疗的患者，剂量为每日60至170毫克，治疗4至24周；另一组为137例患者作为对照组。治疗组123例患者中输血后肝炎的发生率为10例（8.1%），对照组137例患者中为28例（20.4%）。治疗组有1例（0.8%）患者发生黄疸型肝炎，而对照组137例患者中有8例（5.8%）发生黄疸型肝炎。
